导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.65% | 1436/4345 |
| 近一周 | -1.93% | 2812/4962 |
| 近一月 | -2.99% | 1909/4922 |
| 近一季 | -6.96% | 2368/4747 |
| 近半年 | -0.17% | 1285/4477 |
| 近一年 | 7.79% | 1298/4016 |
| 近两年 | 50.19% | 1347/2712 |
| 近三年 | 22.56% | 1259/2054 |
| 成立以来 | 73.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.07% 1689/4961 |
12.90% 2098/5312 |
- - |
- - |
| 2025 | 20.52% 2113/4813 |
-0.33% 2202/3635 |
2.47% 1552/4076 |
14.94% 2857/4524 |
2.67% 886/4813 |
| 2024 | 5.06% 1853/3463 |
-1.01% 1166/2808 |
-2.30% 1170/3014 |
11.37% 2528/3129 |
-2.46% 2091/3463 |
| 2023 | -10.89% 1344/2656 |
3.35% 1212/2280 |
-4.74% 1274/2385 |
-3.88% 1008/2515 |
-5.83% 1521/2655 |
| 2022 | -12.57% 290/2207 |
-9.70% 334/1919 |
7.12% 527/2016 |
-9.40% 275/2113 |
-0.23% 1579/2208 |
| 2021 | 1.38% 677/1822 |
-0.99% 413/1255 |
4.96% 834/1330 |
-3.87% 663/1466 |
1.48% 912/1822 |
| 2020 | 43.33% 246/1250 |
-5.23% 404/1028 |
16.87% 407/1067 |
16.10% 169/1164 |
11.47% 538/1184 |
| 2019 | 43.46% 192/1092 |
23.38% 554/754 |
0.92% 150/804 |
6.53% 123/850 |
8.15% 348/918 |
| 2018 | -19.59% 172/834 |
- - |
- - |
- - |
-11.23% 270/691 |
| 2017 | 1.55% 451/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 万家沪深300指数增强A VS. 长安沪深300非周期A(740101) |